Official Title A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY

Purpose

The purpose of this 28-week study to investigate the effects and safety of a medication in participants with Center Involving Diabetic Macular Edema (CI-DME). .

Could this study be right for you?

• 18 years and older
• Macular edema associated with diabetic retinopathy (DR)
• Diagnosis of diabetes mellitus (DM)

Age Range

18 and up

Official Title Mindfulness-based cognitive therapy for comorbid depression and type 2 diabetes

Purpose

The aim of this study is to improve mood and diabetes-related outcomes for those with type 2 diabetes mellitus (T2DM) AND symptoms of depression. The present study will examine the effect of mindfulness-based cognitive therapy (MBCT) on symptoms of depression and diabetes.

Your participation in this study will last 8 weeks.

Could this study be right for you?

You may qualify if:

• You are between the ages 18-75
• You have type 2 diabetes
• You are feeling symptoms of depression

Age Range

18 and up

Official Title Linking Education, Produce Provision, and Community Referrals to Improve Diabetes Care (LINK)

Purpose

The purpose of this study is to improve hemoglobin A1c levels in patients with type 2 diabetes experiencing food insecurity.

The study will examine the effects of a produce referral program alone and in combination with other interventions. Our research is designed to develop a deeper understanding of how to provide patients with type 2 diabetes that are experiencing food insecurity with the resources, skills, and education to manage their health and social needs.

Could this study be right for you?

Inclusion Criteria:

• Age 18 years and older
• Type 2 diabetes based on American Diabetes Association Criteria
• Hemoglobin A1c level > 7.5%
• Worried about running out of food before you have money to buy more

Exclusion Criteria:

• Pregnant

Official Title DBS-Expert: Automated Deep Brain Stimulation Programming Using Functional Mapping Phase II

Purpose

Deep Brain Stimulation (DBS) surgery is FDA approved for the treatment of Parkinson's Disease. The purpose of this study is to examine a technology (DBS-Expert system) that uses objective measurements to guide DBS programming. The DBS-Expert system analyzes motion data and provides recommendations to the physician or healthcare professional regarding DBS programming settings.

Could this study be right for you?

You may be eligible if you:

• Over the age of 18
• Able and willing to provide informed consent
• Clinical diagnosis of idiopathic Parkinson's Disease
• Implanted Boston Scientific DBS system

Exclusion Criteria

• You are currently participating in any study with an investigational medicinal product (IMP) or investigational device.

Age Range

18 and up

Official Title A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants with Treatment-resistant Depression

Purpose

The purpose of this study is to see if esketamine nasal spray alone is effective as a medication to improve depressive symptoms in adults with treatment-resistant depression when compared with placebo nasal spray.

The duration of the study consists up to a maximum of 24 weeks.

Could this study be right for you?

• Aged 18 years or older
• Must have had no response (less than 25% improvement) to at least 2 oral antidepressant treatments in the current episode of depression

Age Range

18 and up

Official Title SMALL Talk: Study of Milestones to Advance Language Learning

Purpose

The goal of this study is to identify early risk for developmental language disorder (DLD) among young, low-income children, and to determine how caregiver and child chronic stress and interaction quality interact to disrupt language growth among these children. The long-term objective is to identify pathways through which early family situations and the conditions of poverty disrupt early language paths among low-income children and contribute to heightened rates of DLD.

Could this study be right for you?

Inclusion criteria are:

• have a child that is 9 months or younger
• child resides in a low-income household, using some sort of government assistance or using the 200% threshold from the Department of Health and Human Services based on annual household income and number of persons in home

Exclusion criteria:

• Children who are multiple births, preterm (<35 weeks), and have profound or severe disabilities will be excluded, with the latter including congenital blindness, deafness, Down syndrome, and other frank neurological deficits.

Official Title Mobile Health (mHealth), Breast Disease, and Lifestyle Modification: Developing a Grounded Theory

Purpose

The purpose of this study is to understand breast cancer survivors use of mobile health (mHealth) apps for lifestyle behavior change - eating a healthier diet, exercising more, dealing with stress, & stopping smoking. Interviews will last approximately 60 - 90 minutes.

Could this study be right for you?

• You have a diagnosis of breast disease or are a breast cancer survivor.
• You are age 18 or older
• You are a female

Age Range

18 and up

Official Title Laying the Groundwork for Personalized Medicine in Aphasia Therapy: Genetic and Cognitive Predictors of Restorative Treatment Response

Purpose

This NIH-funded project will investigate patient-specific factors that may influence response to therapy for language impairment after stroke, or aphasia. Results from this work will assist with better estimation of prognosis for stroke survivors with aphasia, which could empower patients and families to make more informed health care decisions about how to pursue the most appropriate rehabilitation services based on their unique characteristics, such as genetics, cognitive skills, and brain structure after stroke.

Could this study be right for you?

Participants must meet the following criteria:

• Native English speaker
• Able to have an MRI

Age Range

18 and up

Official Title A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

Purpose

The purpose of this study is to find out how well ABBV-951 works to control Parkinson's disease symptoms compared to oral Carbidopa (CD)/Levodopa (LD). The study is also seeking to test whether ABBV-951 is well tolerated in patients with Parkinson's disease.

Could this study be right for you?

1. Male or female, age 30 or older
2. Has not received deep brain stimulation, Carbidopa (CD)/Levodopa (LD) enteral suspension, or any other Parkinson's Disease (PD) medication as continuous daily infusion
3. Subject does not have a history of significant skin conditions or disorders
4. Subject does not have a recent (within 6 months before screening) history of drug or alcohol abuse
5. Subject does not have a history or presence of psychotic episodes
6. Subject does not have other clinically significant unstable medical conditions
7. Subject must have a diagnosis of levodopa-responsive idiopathic PD

* other eligibility criteria to be discussed/reviewed with the study team

Age Range

30 and up

Official Title A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II)

Purpose

Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) treatment in cancer patients. The main purpose of this study is to evaluate the safety and efficacy of OQL011 compared to vehicle ointment in treating patients with moderate to severe VEGFRi-associated HFSR. This study will also identify an optimal dosage for Phase III study and explore the pharmacokinetics profile of OQL011 in HFSR patients.

Could this study be right for you?

• Patient must be age 18 years of age or older.
• Patient must have a confirmed cancer diagnosis for which VEGFRi treatment is indicated, and must be currently under VEGFRi-based anti-cancer therapy with stable dosage for ≥ 1 week.
• Patient on pain medications is allowed provided they have been on stable dosage in the past 1 week and is going to continue at the same dosage.

Age Range

18 and up

Official Title A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata (JAHO)

Purpose

The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research questions:
• Whether baricitinib is better than placebo in the treatment of patients with severe alopecia areata (AA)
• The safety of baricitinib and any side effects you may have when you take it.

Could this study be right for you?

• Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent
• Are able to read, understand, and give documented (electronic or paper signature) informed consent
• Current AA episode of more than 6 months’ duration and hair loss encompassing ≥50% of the scalp
• No spontaneous improvement over the past 6 months

Age Range

18 and up

Official Title A Randomized Trial of Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy (SLEEP)

Purpose

The purpose of this study is to understand how Continuous Positive Airway Pressure (CPAP)
for mild to moderate sleep apnea may affect hypertensive disorders of pregnancy and other
complications of pregnancy such as gestational diabetes.

Could this study be right for you?

1. No prior delivery at or after 20 weeks 0 days of gestation
2. Pregnancy with only one fetus
3. Gestational age at randomization between 14 weeks 0 days and 21 weeks 6 days
4. Diagnosis with mild to moderate OSA as defined by an AHI score ≥ 5 and <30

Age Range

18 and up